These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
322 related articles for article (PubMed ID: 30870198)
21. Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV. Teira R; Diaz-Cuervo H; Aragão F; Marguet S; de la Fuente B; Muñoz MJ; Abdulghani N; Ribera E; Domingo P; Deig E; Peraire J; Roca B; Montero M; Galindo MJ; Romero A; Espinosa N; Lozano F; Merino MD; Martínez E; Geijo P; Estrada V; García J; Sepúlveda MA; Berenguer J PLoS One; 2021; 16(4):e0249515. PubMed ID: 33831047 [TBL] [Abstract][Full Text] [Related]
22. Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis. Cruciani M; Parisi SG PLoS One; 2019; 14(9):e0222229. PubMed ID: 31504060 [TBL] [Abstract][Full Text] [Related]
23. Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women With HIV. O'Halloran JA; Wang K; Spence AB; Williams DW; Dastgheyb R; Fitzgerald KC; Kamkwalala AR; Maki PM; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Lahiri CD; Sheth AN; Xu Y; Rubin LH J Acquir Immune Defic Syndr; 2021 Apr; 86(5):593-599. PubMed ID: 33394812 [TBL] [Abstract][Full Text] [Related]
24. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S; Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000 [TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of antiretroviral drug classes for the treatment of HIV infection in patients with high viral loads: a multicentre retrospective cohort study. Adams JL; Murray M; Patel N; Sawkin MT; Boardman RC; Pham C; Kaur H; Patel D; Yager JL; Pontiggia L; Baxter J HIV Med; 2021 Jan; 22(1):28-36. PubMed ID: 32964664 [TBL] [Abstract][Full Text] [Related]
26. Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe. Rossetti B; Fabbiani M; Di Carlo D; Incardona F; Abecasis A; Gomes P; Geretti AM; Seguin-Devaux C; Garcia F; Kaiser R; Modica S; Shallvari A; Sönnerborg A; Zazzi M; HIV Med; 2022 Aug; 23(7):774-789. PubMed ID: 35199909 [TBL] [Abstract][Full Text] [Related]
27. Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana. Bareng OT; Moyo S; Mudanga M; Sebina K; Koofhethile CK; Choga WT; Moraka NO; Maruapula D; Gobe I; Motswaledi MS; Musonda R; Nkomo B; Ramaabya D; Chebani T; Makuruetsa P; Makhema J; Shapiro R; Lockman S; Gaseitsiwe S Viruses; 2024 May; 16(5):. PubMed ID: 38793602 [TBL] [Abstract][Full Text] [Related]
28. INSTI-Based Initial Antiretroviral Therapy in Adults with HIV, the HIV Outpatient Study, 2007-2018. Mayer S; Rayeed N; Novak RM; Li J; Palella FJ; Buchacz K; AIDS Res Hum Retroviruses; 2021 Oct; 37(10):768-775. PubMed ID: 34030459 [TBL] [Abstract][Full Text] [Related]
29. Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor. Spertilli Raffaelli C; Rossetti B; Paglicci L; Colafigli M; Punzi G; Borghi V; Pecorari M; Santoro MM; Penco G; Antinori A; Zazzi M; De Luca A; Zanelli G J Antimicrob Chemother; 2018 Sep; 73(9):2480-2484. PubMed ID: 29945251 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort. Fabbiani M; Rossetti B; Ciccullo A; Oreni L; Lagi F; Celani L; Colafigli M; De Vito A; Mazzitelli M; Dusina A; Durante M; Montagnani F; Rusconi S; Capetti A; Sterrantino G; D'Ettorre G; Di Giambenedetto S; HIV Med; 2021 Oct; 22(9):843-853. PubMed ID: 34318591 [TBL] [Abstract][Full Text] [Related]
31. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen. Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958 [TBL] [Abstract][Full Text] [Related]
32. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978 [TBL] [Abstract][Full Text] [Related]
33. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235 [TBL] [Abstract][Full Text] [Related]
34. Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection. Veil R; Poizot-Martin I; Reynes J; Goujard C; Seng R; Delobel P; Cotte L; Duvivier C; Rey D; Tran L; Surgers L; Allavena C; Lascoux Combe C; Cheret A; Meyer L AIDS; 2020 Mar; 34(4):493-500. PubMed ID: 31764069 [TBL] [Abstract][Full Text] [Related]
35. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort. Cuzin L; Pugliese P; Katlama C; Bani-Sadr F; Ferry T; Rey D; Lourenco J; Bregigeon S; Allavena C; Reynes J; Cabié A; J Antimicrob Chemother; 2019 Mar; 74(3):754-760. PubMed ID: 30534993 [TBL] [Abstract][Full Text] [Related]
36. Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment. Pyngottu A; Scherrer AU; Kouyos R; Huber M; Hirsch H; Perreau M; Yerly S; Calmy A; Cavassini M; Stöckle M; Furrer H; Vernazza P; Bernasconi E; Günthard HF; Clin Infect Dis; 2021 Oct; 73(7):e2134-e2141. PubMed ID: 33095848 [TBL] [Abstract][Full Text] [Related]
37. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. ; Kouanfack C; Mpoudi-Etame M; Omgba Bassega P; Eymard-Duvernay S; Leroy S; Boyer S; Peeters M; Calmy A; Delaporte E N Engl J Med; 2019 Aug; 381(9):816-826. PubMed ID: 31339676 [TBL] [Abstract][Full Text] [Related]
38. Immunological and virological efficacy of different antiretroviral regimens initiated during acute/recent HIV infection. Ambrosioni J; Farrera J; de Lazzari E; Nicolás D; Manzardo C; Hernández-Meneses MM; Mosquera MM; Ligero C; Marcos MA; Sánchez-Palomino S; Fernández E; Plana M; Miró JM; AIDS; 2020 Dec; 34(15):2269-2274. PubMed ID: 32910066 [TBL] [Abstract][Full Text] [Related]
39. Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir. Meireles MV; Pascom ARP; Duarte EC; McFarland W AIDS; 2019 Aug; 33(10):1663-1668. PubMed ID: 31082860 [TBL] [Abstract][Full Text] [Related]
40. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Laprise C; de Pokomandy A; Baril JG; Dufresne S; Trottier H Clin Infect Dis; 2013 Nov; 57(10):1489-96. PubMed ID: 23946221 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]